Restoring Balance In The Gut To Prevent Drug-Resistant Infection
Executive Summary
Silvia Caballero, one of In Vivo’s 2020 Rising Leaders, is heading up Vedanta’s efforts to prevent potentially lethal infections stemming from colonization of the gut microbiome with a novel bacterial cocktail that is nearing clinical development.
You may also be interested in...
Vedanta Receives Cash Injection To Proceed With Microbiome-Derived Pipeline
Vedanta’s latest financing allows it to push three of its microbiome-based drug candidates further into the clinic, with big name partners such as BMS and Janssen onboard.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Moderna Touts mRNA Progress, Plus $750m From Blackstone To Back Its Flu Vaccine
Moderna still projects $4.5bn in R&D spending this year for its pipeline of 28 mRNA vaccines, including a COVID-19 vaccine with stronger immune response than Spikevax.